


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

castration resistant prostate cancer (mCRPC). Ann Oncol 30[Supplement_5], v885.

- Juergens RA, Ellis PM, Tu D, Hao D, Laurie SA, Mates M, Goss G, Goffin J, Bradbury P,
  Update on platinum doublet + combination durvalumab +/- tremelimumab in advanced
  NSCLC: A CCTG phase 1B study - IND.226. IASLC World Conference on Lung Cancer
  19, 308. 2019.

  Wei AC, Chan K, Montenegro A, Loree JM, Tu D, Jonker DJ. CO.28: Neoadjuvant
  Chemotherapy, Excision and Observation (NEO) for early rectal cancer. J Clin Oncol

- Moku PR, Shepherd LE, Ali S, Leitzel K, Parulekar WR, Zhu L, Virk S, Nomikos D,
  Apricio S, Gelmon KA, Drabick J, Cream L, Halstead S, Polimera HV, Maddukurki A,
  and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line

- Olson D, Bao R, Allred JB, Strand C, Zha Y, Carl TC, Labadie B, Bastos BR, Butler MO,
  Munster PN, Schwartz GK, Luke JJ. Correlates of overall survival (OS) in metastatic
  uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus

- Parulekar WR, Berrang T, Kong I, Rakovitch E, Theberge V, Gelmon KA, Chia SKL,
  Bellon JR, Jagsi R, Ho AY, White JR, Zellars RC, Bane A, Boileau J-F, Lemieux J,
  Montenegro A, Chen BE, Whelan TJ. Cctg MA.39 tailor RT: A randomized trial of
  regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).

- Pimental I, Chen BE, Lohmann AE, Ennis M, Ligibel JA, Shepherd LE, Hershman DL,
  Stambolic V, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Rastogi P, Gelmon KA,
  Whelan TJ, Rabaglio-Poretti M, Dowling RJO, Parulekar WR, Goodwin PJ. The effect of
  metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A
  Phase III randomized adjuvant trial of metformin versus placebo in addition to standard

- Roth P, Reijneveld JC, Gorlia T, Dhermain F, De Vos FYFL, Vanlancker M, O’Callaghan
  CJ, Le Rhun E, van den Bent MJ, Mason WP, Weller M. EORTC 1709/CCTG CE.8: A
  phase III trial of marizomib in combination with standard temozolomide-based
  radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in
  patients with newly diagnosed glioblastoma. J Clin Oncol 37[Suppl; abstr TPS2072].
  2019.

- Sparano JA, Gray RJ, Makower DF, Lively TG, Saphner TJ, Keane MM, Gomez HL,
  Reddy PS, Goggins TF, Mayer IA, Toppmeyer D, Brufsky A, Goetz MP, Hayes DF, Dees
  EC, Pritchard KI, Geyer CE, Olson JA, Albain KS, Sledge GW. Impact of clinical risk
  category on prognosis and prediction of chemotherapy benefit in early breast cancer
  (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. J Clin Oncol

- Sweeney C, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN,
  Pook DW, Parnis F, North SA, McDermott R, McCaffrey J, Marx GM, Lawrence NJ,
  Horvath L, Frydenberg M, Chowdhury S, Chi KN, Stockler MR, Davis ID. Overall survival
  (OS) results of a phase III randomized trial of standard-of-care therapy with or without
  enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET
  (ANZUP 1304), an ANZUP-led international cooperative group trial. J Clin Oncol


- Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL,


Daaboul N, Gauthier I, Tu D, Brown-Walker P, Sun X, Hao D, Juergens RA, Bradbury PA, Mates M, Tehfe MA, Kollmannsberger CK, Ellis PM, Robinson AG, Wheatley-Price P, Laurie SA, Seymour L. Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226. J Clin...


2016

- Abou-Alfa GK, Niedzwiecki D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R,


• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)] 2015.


stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). J Clin Oncol 33[suppl; abstr 1033].


- Lohmann AE, Chapman J-AW, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI,


cyclophosphamide followed by Paclitaxel (AC/T) in a randomized trial (RCT), compared to a case-control matched British Columbia (BC) breast cancer population. J Clin Oncol 32:5s[suppl; abstr 1037]. 2014.


2013


Lymphoproliferative Disorders, 2013.

- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.
- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2012

BIG-NABCG investigators. Quantitative hormone receptors, triple negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. J Clin Oncol 30[suppl, abstr 1008], 2012.


German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood (ASH Annual Meeting Abstracts) 120[21, abstr 548], 2012.


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KL, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


• Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). J Clin Oncol 30[suppl, abstr TPS5600], 2012.


- Basik M, Keilty D, Aleynikova O, Tu D, Li X, Shepherd LE, Bramwell V. Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG


- Dong B, Chapman J-AW, Yerushalmi R, Goss PE, Pollak MN, Burnell MJ, Bramwell VH,


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


• Soulieres D, Fortin B, Winquist E, Charpentier D, Harnett E, Walsh W, Parulekar W. HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN. J Clin Oncol 28[15s, abstr 5562], 2010.


• Verleye L, Ottevanger PB, Amant F, Kristensen GB, van der Burg MEL, Verheijen R,


2009


• Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27[15s], 2009.


• Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


• Ding K, Shepherd FA, Tsao MS, Le Maître A, Seymour L. P53 IHC protein expression and tumor size predict survival benefit from adjuvant chemotherapy in stage IB non small cell lung cancer patients. BIT’s 2nd Annual World Cancer Congress, 2009.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

Symposium, 2009.

- Laurie SA, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Goss G,
Ding K, Seymour L. Overall survival results of NCIC Clinical Trials Group BR.24: A randomized, double-blind trial of carboplatin + paclitaxel with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinase. J Thoracic Oncol 4[9 suppl 1, abstr C1.1], S353. 2009.


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


- Strevel EL, Ding K, Seymour L, Tsao MS, Le Maître A, Shepherd FA, Burkes RL.


2008


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


2007


- Au H-J, Brundage M, Ringash J, Bezjak A, Palmer M, Richardson H, Lee CW, Maunsell E, Brotto L, Sussman J, Davis A, Osoba D. Added value of health-related quality of life outcomes in NCIC CTG clinical trials: results from QOL committee workshop. Quality of


- Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle J, Muss H, Palmer M, Yu C,


Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide versus RT alone. 


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2007.


- Tsao MS, Lau S, Boutros P, Pintilie M, Zhu C-Q, Strumpf D, Penn L, Jurisica I, Shepherd FA. Gene expression prognostic classifiers for early stage non-small cell lung


- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


2006


Goldberg RM, McLeod HL, Sargent DJ, Morton RF, Green EM, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. Genetic polymorphisms, toxicity,
and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. J Clin Oncol 24[18S Part 1, abstr 3503]. 2006.


- O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrusis I, Pritchard Ki. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


2005


• Au H, Goldstein D, Ding K, Parulekar W, Gallinger S, Moore M. Does epidermal growth factor receptor inhibitor skin toxicity affect QOL? Results from a NCIC Clinical Trials Group. Quality of Life Research 14[9], 2135, 2005.


• Chapman JW, Jasani B, Ibrahim M, Miller K, Murray D, Hewlett B, Daidone MG, Allred
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.
• Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


• Maunsell E, Au H, Palmer M, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Quality of Life Research 14[9], 2092, 2005.

• Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


• Seymour L, Goss G. Epidermal growth factor receptor tyrosine kinase inhibitors: is dose
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.


2004


- Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldberg SL, Gleave


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


- Goss P, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D,


- Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal


• Li D. A SAS macro to automate the covariance structure determination in repeated measures data analysis with mixed procedure. Pharmaceutical Industry SAS Users Group, 2003.


• Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


2002


- Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2001


• Goss G, Hirte H, Lorimer I, Miller W, Stewart DJ, Batist G, Matthews S, Douglas L,


Parulekar W, Trudeau M, Shepherd L, Ottaway J, Day A, Franssen E, Bramwell V,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2000


- Oza A, Eisenhauer E, Swenerton K, Elit L, Ghatage P, Carey M, Faught W, McIntosh L,

- Walker H, Stuart G, Bacon M, Eisenhauer E, Bacon E, Tu D, Zee B. Comparative cost-
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1999


• Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. The palliative effect of chemotherapy in


• Gertler SZ, Macdonald D, Goodyear M, Forsyth P, Stewart,DJ, Seymour L, Wainman N.


- Pater J, Bezjak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC Clinical Trials Group studies: Have we learned anything new? Ann.Oncol. 9(suppl 4),
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

142, 1998.

- Zhao F, Tu D, Pater J. Bootstrap variable selection and model validation for a Cox's

1997


• Tu D. Statistical procedures in therapeutic equivalence clinical trials with ordered
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1996


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


1995


- Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B. Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin.

Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Supportive Care in Cancer 3(5), 344, 1995.


1994


- Zee B, James K, Johnston D. Design and analysis of late randomization trials: information from time to first response in multiple myeloma. Joint ASA and Biometric

1993


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
- Zee B. One-sided test for clinical trials with group sequential design that allow early


1990


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

304, 1990.


1989


• Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988


1987

1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983


1981
